HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma.
作者信息
Stevens Wendy B C, Bakunina Katerina, Cuijpers Marloes, Chamuleau Martine, Beeker Aart, Fijnheer Rob, Hebart Holger, Visser Hein P J, Doorduijn Jeanette K, Linton Kim, Dreyling Martin, de Jong Daphne, Kersten Marie José
机构信息
Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.
HOVON Data Center, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
出版信息
Hemasphere. 2020 Jan 3;4(1):e325. doi: 10.1097/HS9.0000000000000325. eCollection 2020 Feb.
Abstract
摘要
相似文献
1
HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma.HOVON110/ReBeL研究：来那度胺、利妥昔单抗联合或不联合苯达莫司汀用于复发/难治性滤泡性淋巴瘤患者的随机I/II期研究I期部分的结果
Hemasphere. 2020 Jan 3;4(1):e325. doi: 10.1097/HS9.0000000000000325. eCollection 2020 Feb.
2
A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.来那度胺治疗 B 细胞非霍奇金淋巴瘤的全面综述。
Ann Oncol. 2015 Aug;26(8):1667-77. doi: 10.1093/annonc/mdv102. Epub 2015 Feb 23.
3
Bendamustine-120 plus rituximab therapy for relapsed or refractory follicular lymphoma: a multicenter phase II study.苯达莫司汀-120 联合利妥昔单抗治疗复发或难治性滤泡性淋巴瘤：一项多中心 II 期研究。
Ann Hematol. 2019 Sep;98(9):2131-2138. doi: 10.1007/s00277-019-03750-7. Epub 2019 Jul 8.
4
Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.idelalisib、来那度胺和利妥昔单抗在复发难治性淋巴瘤中的安全性和耐受性：肿瘤临床试验联盟A051201和A051202 1期试验
Lancet Haematol. 2017 Apr;4(4):e176-e182. doi: 10.1016/S2352-3026(17)30028-5. Epub 2017 Mar 15.
5
Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial.来那度胺联合利妥昔单抗治疗复发或难治性弥漫大 B 细胞、滤泡性和转化淋巴瘤：一项 II 期临床试验。
Leukemia. 2013 Sep;27(9):1902-9. doi: 10.1038/leu.2013.95. Epub 2013 Apr 2.
6
Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study.奥妥珠单抗联合来那度胺治疗复发或难治性滤泡性B细胞淋巴瘤（GALEN）：一项多中心、单臂、2期研究。
Lancet Haematol. 2019 Aug;6(8):e429-e437. doi: 10.1016/S2352-3026(19)30089-4. Epub 2019 Jul 8.
7
Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma.套细胞淋巴瘤复发/难治患者中阿卡替尼与其他靶向治疗药物疗效和安全性的匹配调整间接比较。
Clin Ther. 2019 Nov;41(11):2357-2379.e1. doi: 10.1016/j.clinthera.2019.09.012. Epub 2019 Nov 4.
8
Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study.硼替佐米、苯达莫司汀和利妥昔单抗治疗复发或难治性滤泡性淋巴瘤患者：Ⅱ期 VERTICAL 研究。
J Clin Oncol. 2011 Sep 1;29(25):3389-95. doi: 10.1200/JCO.2010.32.1844. Epub 2011 Aug 1.
9
Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas.来那度胺联合小剂量地塞米松和利妥昔单抗治疗利妥昔单抗耐药的惰性和套细胞淋巴瘤可获得持久缓解。
Cancer. 2014 Jan 15;120(2):222-8. doi: 10.1002/cncr.28405. Epub 2013 Oct 7.
10
Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial.伊布替尼、来那度胺和利妥昔单抗治疗复发或难治性套细胞淋巴瘤（PHILEMON）：一项多中心、开放标签、单臂、2期试验。
Lancet Haematol. 2018 Mar;5(3):e109-e116. doi: 10.1016/S2352-3026(18)30018-8. Epub 2018 Jan 29.
引用本文的文献
1
An Overview of Lenalidomide in Combination with Rituximab for the Treatment of Adult Patients with Follicular Lymphoma: The Evidence to Date.来那度胺联合利妥昔单抗治疗滤泡性淋巴瘤成人患者的概述：现有证据。
Drug Des Devel Ther. 2021 Sep 7;15:3809-3820. doi: 10.2147/DDDT.S281614. eCollection 2021.
2
Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future.自然杀伤细胞疗法治疗血液系统恶性肿瘤：成功、挑战与未来。
Stem Cell Res Ther. 2021 Mar 25;12(1):211. doi: 10.1186/s13287-021-02277-x.
本文引用的文献
1
Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy.滤泡性淋巴瘤患者一线治疗中利妥昔单抗联合来那度胺的短疗程方案。
Blood. 2019 Jul 25;134(4):353-362. doi: 10.1182/blood-2018-10-879643. Epub 2019 May 17.
2
Phase 1 study of lenalidomide, bendamustine, and rituximab in previously untreated patients with chronic lymphocytic leukemia.来那度胺、苯达莫司汀和利妥昔单抗治疗初治慢性淋巴细胞白血病患者的 1 期研究。
Leuk Lymphoma. 2019 Dec;60(12):2931-2938. doi: 10.1080/10428194.2019.1608533. Epub 2019 May 10.
3
Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma.来那度胺-苯达莫司汀-利妥昔单抗治疗未经治疗的老年套细胞淋巴瘤患者。
Blood. 2016 Oct 6;128(14):1814-1820. doi: 10.1182/blood-2016-03-704023. Epub 2016 Jun 27.
4
Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma.来那度胺在B细胞非霍奇金淋巴瘤中的作用机制
J Clin Oncol. 2015 Sep 1;33(25):2803-11. doi: 10.1200/JCO.2014.59.5363. Epub 2015 Jul 20.
5
Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.来那度胺和利妥昔单抗用于未经治疗的惰性淋巴瘤的安全性及活性：一项开放标签的2期试验
Lancet Oncol. 2014 Nov;15(12):1311-8. doi: 10.1016/S1470-2045(14)70455-3. Epub 2014 Oct 15.
6
Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma.来那度胺联合利妥昔单抗可使复发或难治性惰性非霍奇金淋巴瘤患者产生持久的临床反应。
Br J Haematol. 2014 May;165(3):375-81. doi: 10.1111/bjh.12755. Epub 2014 Mar 7.
7
Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma.来那度胺单药治疗可使复发或难治性惰性非霍奇金淋巴瘤产生持久缓解。
J Clin Oncol. 2009 Nov 10;27(32):5404-9. doi: 10.1200/JCO.2008.21.1169. Epub 2009 Oct 5.
8
Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy.滤泡性淋巴瘤细胞诱导 T 细胞免疫突触功能障碍，来那度胺可修复该障碍：对肿瘤微环境和免疫治疗的影响。
Blood. 2009 Nov 19;114(21):4713-20. doi: 10.1182/blood-2009-04-217687. Epub 2009 Sep 28.
9
Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo.来那度胺与利妥昔单抗对套细胞淋巴瘤的体内外协同抗肿瘤作用
Am J Hematol. 2009 Sep;84(9):553-9. doi: 10.1002/ajh.21468.
10
lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.来那度胺增强利妥昔单抗治疗的CD20+肿瘤细胞的自然杀伤细胞和单核细胞介导的抗体依赖性细胞毒性。
Clin Cancer Res. 2008 Jul 15;14(14):4650-7. doi: 10.1158/1078-0432.CCR-07-4405.
Zotero 插件